MicroTransponder is a U.S.-based, growth-stage company commercializing the Vivistim Paired VNS System, an implantable neurostimulation therapy that improves outcomes for chronic ischemic stroke survivors with upper limb motor deficits.

Vivistim Paired VNS System is an implantable neurostimulation therapy that helps stroke survivors regain upper limb motor function. Vivistim is the first PMA-approved therapy for chronic stroke patients, and its use is supported by a triple-blinded, sham control, randomized control trial published in The Lancet in 2021. The device stimulates the vagus nerve during rehab exercises, promoting neuroplasticity and restoring movement in patients who have reached the chronic stroke phase, where traditional therapy is ineffective. To drive adoption of this therapy, MicroTransponder is engaged in a robust market development effort: they are educating neurosurgeons and therapists, building out new referral patterns, and driving payer coverage. The company aims to make Vivistim Standard of care for all eligible chronic stroke patients over the next 5 to 10 years.

In February of 2025, Gilde invested $10M into a $65M Series F round to further scale commercialization efforts and continue developing the clinical evidence base. Gilde will take a seat on the board of directors and advise the company as it navigates commercial, manufacturing, reimbursement, and capital markets related challenges during this growth phase.